HLA-C and cancer: Notably, NST ER−/HER2− cancer cells from obese patients expressed lower levels of major histocompatibility complexes class I (MHC-I) (HLA-B, HLA-C) (Fig. 5i), suggesting a potential niche for evasion of anti-tumor immunity50.